Is Sotorasib on the market?

Sotorasib (Sotorasib) is the first experimental KRAS inhibitor. The drug MRTX849 is also currently under development and has the same target. It was approved for marketing by the US Food and Drug Administration (FDA) on May 28, 2021, and was subsequently approved for marketing by the European Commission on January 10, 2022. Sotorasiibis an acrylamide-derived KRAS inhibitor developed by Amgen (Amgen), also known as AMG-510, for thetreatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutations.

Mutant KRAS was discovered in 1982, but was not considered a druggable target until the mid-2010s. Most trial participants with non-small cell lung cancer had previously received immunotherapy and/or chemotherapy. Everyone in the study received once-daily sotorasiib until their disease worsened and they had to stop taking it because of side effects. Among 124 evaluable NSCLC patients, 4 had complete tumor disappearance and 42 had partial tumor shrinkage. Another 54 people were in stable condition, meaning their cancer was not getting better or getting worse.

SotoracibThe original drug has not yet been launched in China, so it is not covered by medical insurance. Domestic patients cannot yet purchase this drug. The price of Hong Kong original research versionsotorasibuSpecifications120mg*240 tablets is about RMB 80,000, and the European original research version 120mg*240 tablets is priced at about RMB 44,040 (the price may fluctuate due to the exchange rate), which is relatively expensive. There are also cheaper generic drugs for sale in other countries. The specifications of the Laos Element Pharmaceutical Factory are 120mg*56 tablets and the price is around 4800 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of foreign generic drugs are basically the same as the original drugs.